Liminal BioSciences

Liminal BioSciences is a development-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate G protein-coupled receptor pathways.

The company targets metabolic, inflammatory, and fibrotic diseases using an integrated drug discovery platform combining medicinal chemistry expertise with deep GPCR biology.

UK operations are based at Iconix Park, Sawston, and form one of two primary research hubs alongside Laval, Quebec.